MILLIPLEX® Multiplex Assays for Cytokine, Chemokine and Other Immune Biomarker Assays for Luminex®

Immunology Multiplex Biomarker Detection



Multiplex immune biomarkers and cytokine assays

Measure biomarkers of inflammation and immune response with MILLIPLEX® multiplex assays. For the full listing, download our Analyte Quarterly brochure.

Quantifying cytokines and other proteins is important for understanding pathological states such as inflammation, sepsis, and diseases (such as autoimmune disease, cardiovascular disease, metabolic syndrome, neurological disorders and cancer). Our wide ranging immunology panel offering includes kits to measure cytokines, chemokines, growth factors, soluble cytokine receptors, checkpoint proteins, complement proteins, autoimmune autoantibodies, TIMPs, MMPs, sepsis related proteins, skin biomarkers, TGFβ, and immunoglobulins.

Based on Luminex® xMAP® technology, our multiplex immunology assays enable precise, multiparametric analysis of diseases and underlying processes.


 Highlighted interview with our collaborator

Meet Mary Young, Research and Laboratory Technician

University of Virginia, School of Medicine, Division of Infectious Diseases


Mary has her Bachelor of Science in Biology from Elon University. She joined the Petri Lab 3 years ago as a research technician helping with several projects, mainly focusing on human immune response to C. difficile infection. When the pandemic hit Virginia in March, Mary helped establish a biorepository of plasma collected from patients tested for COVID-19 infection at UVA and has been focusing on human immune response to SARS-CoV-2. 

Briefly describe your lab’s research interest area.

The Petri Lab focuses on disease pathogenesis and host immune response of several infections of the gastrointestinal system including Entamoeba histolytica, Clostridioides difficile, and Cryptosporidiosis. The lab also investigates the impact on childhood development of these enteric infections through our partnership with ICDDR, B; International Centre for Diarrhoeal Disease Research, Bangladesh. With our expertise as an immunology lab, we have been able to quickly shift focus to COVID-19 research.

Describe your recent COVID-19 studies and any published work related to COVID-19.

We currently have several projects focusing on COVID-19. We were able to set up a biorepository of plasma samples from patients tested for COVID-19 at UVA in March just as the pandemic hit Virginia. With those samples, we have measured cytokines and chemokines, antibodies, and metabolites. We have also established a COVID-19 mouse model allowing us to start better understanding biological processes causing clinical symptoms in humans.

Why did you choose MILLIPLEX® assays for your COVID-19 research?

Multiplex assays are very beneficial when asking a new research question, especially with a new disease like COVID-19. We trusted the proven specificity and sensitivity of MILLIPLEX® assays, so we knew that we would not be wasting precious samples.

We used MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A and the new MILLIPLEX® SARS-CoV-2 Antigen Panels, allowing us to measure 48 cytokines and 12 SARS-CoV-2 antigens with less than 75 µL of plasma.

How does using MILLIPLEX® assays help your research and/or workflow?

MILLIPLEX® assays save valuable time and sample by allowing us to measure several targets at once. We also only have to thaw plasma samples once, lessening the risk of sample degradation.

What other great work is being done in your laboratory?

While we have swung some of our focus to COVID-19 this year, we are still working on projects pertaining to Entamoeba histolytica, Clostridioides difficile, and Cryptosporidiosis. Our lab has published several articles recently, including type-2 immunity and predicting disease outcomes in C. difficile infection, how the gut microbiome regulates susceptibility to amebiasis, and type-2 immunity in E. histolytica infection.

If you could solve any challenge in research, what would it be?

Public opinion and awareness of research. It is very difficult to find support for basic academic research that is required for life-saving drugs if people are generally not aware or just don't care about it. It takes years to come up with disease treatments, and it is hard to garner support without a flashy end product. Not only do I think it is important to understand basic science and research process, but it may also inspire more people to enter STEM fields.

How have you been spending your free time during the pandemic?

Spending more time with my dog! We have been exploring all the trails that Charlottesville has to offer. Like most dogs, I think he is very much enjoying me being home more during the pandemic.

Read recent publications from Mary Young and the Petri Lab:

Young MK, Kornmeier C, Carpenter RM, Natale NR, Sasson JM, Solga MD, et al. IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10. medRxiv 2020.12.05.20244541; doi:

Sasson JM, Campo JJ, Carpenter RM, Young MK, Randall AZ, Trappl-Kimmons K, et al. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients. medRxiv 2021.01.12.21249702; doi:

Listen to Mary’s webinar on-demand: IgG Antibodies Against SARS-CoV-2 Correlate to Days from Symptom Onset in COVID-19 Positive Patients

Learn more about our MILLIPLEX® COVID-19 Applications.

For Research Use Only. Not For Use In Diagnostic Procedures.

Popular Analytes*
Cytokines/Chemokines Autoantibodies Complement Factors TIMPs and MMPs
Factor D
Factor H
*Only selected analytes listed